NKGen Biotech, Inc. Common Stock
NKGN
NKGN was delisted on the 4th of March, 2025.
3 hedge funds and large institutions have $161K invested in NKGen Biotech, Inc. Common Stock in 2025 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 23 closing their positions.
23.52% less ownership
Funds ownership: 23.52% → 0% (-24%)
88% less funds holding
Funds holding: 25 → 3 (-22)
96% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 23
97% less capital invested
Capital invested by funds: $5.07M → $161K (-$4.91M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FTUS
Flow Traders U.S.
New York
|
+$25.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pathstone Holdings
Englewood,
New Jersey
|
-$1.83M |
| 2 |
MC
Meteora Capital
Boca Raton,
Florida
|
-$1.82M |
| 3 |
KC
Kepos Capital
New York
|
-$151K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$149K |
| 5 |
UOC
University of Chicago
Chicago,
Illinois
|
-$116K |
NKGN Hedge Fund Activity: Q1 2025 in Review
3 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Common Stock (NKGN) for Q1 2025, worth a combined $161K — down 97% from $5.07M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of NKGN and 1 opened new positions — a net loss of 22 holders — while 1 trimmed existing stakes and 0 added.
The largest buyer was Flow Traders U.S., opening a new position worth an estimated $25.5K. The largest seller was Pathstone Holdings, exiting entirely with an estimated $1.83M sold.
- 3 institutional investors held NKGen Biotech, Inc. Common Stock (NKGN) as of Q1 2025, down from 25 in Q4 2024.
- Funds reported $161K of NKGen Biotech, Inc. Common Stock stock for Q1 2025, down 97% quarter-over-quarter.
- 1 fund opened new NKGen Biotech, Inc. Common Stock positions in Q1 2025 and 23 closed out, a net change of -22 holders.
- The largest NKGen Biotech, Inc. Common Stock buyer in Q1 2025 was Flow Traders U.S., an estimated $25.5K added.
- The largest NKGen Biotech, Inc. Common Stock seller in Q1 2025 was Pathstone Holdings, an estimated $1.83M sold.
Based on aggregated 13F filings for Q1 2025.